Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dipyrone + hyoscine butylbromide
- Development stage
- Unknown
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CDE100 is a fixed-dose combination drug developed by the Brazilian pharmaceutical company EMS, consisting of dipyrone (metamizole) and hyoscine butylbromide (scopolamine butylbromide). Dipyrone is a non-opioid analgesic and antipyretic that provides pain relief by inhibiting cyclooxygenase (COX) enzymes and modulating central pain pathways. Hyoscine butylbromide is a quaternary ammonium antispasmodic that antagonizes muscarinic acetylcholine receptors in smooth muscle, specifically targeting the uterine and gastrointestinal tracts to relieve cramps. This combination is primarily indicated for the treatment of pain and spasms associated with primary dysmenorrhea (menstrual cramps). CDE100 was evaluated in a Phase III crossover clinical trial (NCT04446325) to demonstrate therapeutic equivalence to the reference product, Buscopan Composto.
- Brand names
- Atroveran Composto
- Other names
- metamizole + hyoscine butylbromidedipirona + brometo de butilescopolaminaCDE100 associationCDE-100 associationCDE 100 association
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CHRM3 (M3)PGHS-1 (Prostaglandin G/H Synthase 1)CHRM2 (M2)CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on dipyrone + hyoscine butylbromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dipyrone + hyoscine butylbromide.